MedPath

Vasopressin

Generic Name
Vasopressin
Brand Names
Vasostrict
Drug Type
Small Molecule
Chemical Formula
C92H130N28O24S4
CAS Number
11000-17-2
Unique Ingredient Identifier
Y87Y826H08

Overview

Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V and V cellular receptors. The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock. It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.

Background

Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V and V cellular receptors. The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock. It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.

Indication

1.诊断和治疗由于缺乏抗利尿激素而引起的尿崩症,也用于其他药物效果不佳的腹部肌肉松弛; 2.脑外科手术后或头颅创伤后多尿的初期治疗; 3.用于食管、胃肠道消化道疾病的急性大出血的辅助治疗。

Associated Conditions

  • Acute Circulatory Failure

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2024/03/04
Phase 4
Not yet recruiting
2024/01/31
Not Applicable
Recruiting
King's College Hospital NHS Trust
2024/01/22
Phase 4
ENROLLING_BY_INVITATION
2023/07/24
Phase 2
Recruiting
2023/04/10
Phase 4
Recruiting
2023/02/21
Phase 1
Recruiting
2022/10/05
Phase 3
Recruiting
2022/04/07
Not Applicable
UNKNOWN
2022/01/14
Phase 4
Withdrawn
2021/05/18
Not Applicable
Completed
University of Electronic Science and Technology of China

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Eugia US LLC
55150-370
INTRAVENOUS
20 [USP'U] in 1 mL
11/7/2023
Par Pharmaceutical, Inc.
42023-268
INTRAVENOUS
1 [USP'U] in 1 mL
11/16/2023
Par Pharmaceutical, Inc.
42023-164
INTRAVENOUS
20 [USP'U] in 1 mL
3/6/2023
Baxter Healthcare Corporation
0338-9640
INTRAVENOUS
20 [USP'U] in 100 mL
9/29/2023
Eugia US LLC
55150-370
INTRAVENOUS
20 [USP'U] in 1 mL
8/4/2023
Par Pharmaceutical, Inc.
42023-219
INTRAVENOUS
0.4 [USP'U] in 1 mL
11/16/2023
Par Pharmaceutical, Inc.
42023-190
INTRAVENOUS
20 [USP'U] in 1 mL
11/16/2023
Par Pharmaceutical, Inc.
42023-237
INTRAVENOUS
0.2 [USP'U] in 1 mL
11/16/2023
Baxter Healthcare Corporation
0338-9647
INTRAVENOUS
40 [USP'U] in 100 mL
9/29/2023
Fresenius Kabi USA, LLC
65219-039
INTRAVENOUS
20 [USP'U] in 1 mL
7/1/2022

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath